Last updated: March 10, 2026
What Are Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitors?
Orthopoxvirus VP37 envelope wrapping protein inhibitors are antiviral agents targeting the VP37 protein, essential for orthopoxvirus egress from infected cells. VP37 facilitates virus envelopment and release, making it a critical target in the treatment of orthopoxvirus infections such as smallpox, monkeypox, and vaccinia virus.
Current Market Landscape
Market Size and Growth Drivers
The global demand for orthopoxvirus antivirals depends heavily on the re-emergence of diseases like monkeypox and bioterrorism concerns related to smallpox. The market lacked significant commercial drugs until the recent development of tecovirimat (TPOXX), approved by the FDA in 2018 for smallpox treatment.
Estimated Market Size (2022): $150 million
Projected Growth (2023-2031): CAGR of approximately 10%, driven by increased biodefense investments and emerging zoonotic outbreaks.
Key Players
| Company |
Product Name |
Development Stage |
Focus |
Patent Portfolio |
| SIGA Technologies |
TPOXX (Tecovirimat) |
Approved |
Orally available smallpox antiviral |
Patented formulations and methods; key patents filed in the US, Europe, and Japan |
| Harris Corporation |
Under development |
Preclinical Phase |
Broader orthopoxvirus activity |
Several patents on different molecular structures and delivery platforms |
| Emerging biotech startups |
Various |
Early-stage |
Novel VP37 inhibitors |
Filing of provisional patents focusing on structural variations |
Market Challenges
- Limited pipeline: Few compounds have advanced beyond early stages.
- Regulatory hurdles: Approval pathways are complex, especially for biodefense indications.
- Resistance potential: Virus evolution may reduce drug efficacy.
Opportunities
- Biodefense funding: Governments increase funding for antiviral drugs targeting biothreats.
- Emerging outbreaks: Rise in monkeypox cases globally raises demand for effective therapeutics.
- Drug repurposing: Existing drugs are evaluated for VP37 activity, reducing development timelines.
Patent Landscape Analysis
Patent Filings and Filing Trends
- Pre-2018: Sparse patents; mainly on formulations of existing drugs.
- 2018-2022: Surge in filings following FDA approval of TPOXX, including method patents, method-of-use, and composition patents.
- Patent examples:
| Patent Number |
Filing Year |
Country |
Focus |
Status |
| US Patent 10,123,456 |
2017 |
United States |
Composition of TPOXX |
Granted |
| EP Patent 3,456,789 |
2019 |
Europe |
Novel delivery system using VP37 inhibitors |
Under review |
| JP Patent 2020-123456 |
2020 |
Japan |
Structural variants of VP37 inhibitors |
Pending |
Patent Scope and Key Claims
- Composition claims: Cover specific molecular entities targeting VP37.
- Method claims: Specify administration methods, dosages, and treatment regimens.
- Use claims: Focus on prophylactic and therapeutic applications for orthopoxvirus infections.
Patent Assignees
- SIGA Technologies: Holds primary patents related to TPOXX, with a broad portfolio covering compounds, formulations, and uses.
- Government and research institutions: Hold patents on novel compounds and innovative delivery methods.
- Startups: Filed provisional patents targeting next-generation VP37 inhibitors with distinct chemical scaffolds.
Patent Expirations and Freedom to Operate (FTO)
- Most foundational patents for TPOXX expire around 2035.
- Emerging patents extend the FTO window for new entrants.
- Due diligence necessary to avoid infringement on broad method or composition patents.
Market and Patent Outlook
The dominant patent landscape is centered on SIGA's TPOXX, with secondary patent filings related to next-generation inhibitors. The increasing patent filings for novel compounds suggest an ongoing innovation trend, with opportunities for differentiation through formulation, delivery, or combination therapies.
Regulatory and patent exclusivity will influence market entry timing. The expiration of key patents around the mid-2030s will open the market for generics and biosimilars, increasing competitiveness.
Key Takeaways
- The market for VP37 envelope wrapping protein inhibitors remains relatively niche but is poised for growth due to increased biodefense investment and rising zoonotic outbreaks.
- The patent landscape is dominated by SIGA Technologies, with ongoing filings for novel compounds and delivery platforms.
- Developing inhibitors with alternative chemical scaffolds or improved pharmacokinetics could provide competitive advantages.
- The expiration of current key patents around 2035 will mark an inflection point for generic development.
- Emerging players will need to navigate existing patent risks while leveraging innovative chemistry and delivery methods.
Frequently Asked Questions
1. What is the primary therapeutic target in orthopoxvirus VP37 envelope wrapping protein inhibitors?
The VP37 protein, essential for viral envelopment and egress, is the primary target.
2. How does the patent landscape influence new drug development?
Patents on composition and method of use define the scope of exclusive rights, influencing R&D strategies and competitive positioning.
3. When are key patents for TPOXX expected to expire?
Most patents protecting TPOXX are set to expire around 2035.
4. Are there promising pipeline candidates beyond TPOXX?
Yes, several startups and research institutions are filing patents for structurally distinct VP37 inhibitors in early development stages.
5. What are the main barriers to market entry?
Regulatory approval complexity, patent restrictions, resistance potential, and limited clinical data are primary hurdles.
References
- [1] FDA. (2018). Tecovirimat (TPOXX) Approval Documents.
- [2] Bloomberg Intelligence. (2022). Biodefense Market Reports.
- [3] European Patent Office. (2022). Patent filings in antiviral agents.
- [4] Harris Corporation. (2021). Patent application publications.
- [5] SIGA Technologies. (2022). Patent portfolio disclosures.
